Update on the molecular signature of differentiated thyroid cancer: clinical implications and potential opportunities

References

• Schreiner BF, Murphy WT. Malignant neoplasms of the thyroid gland. Ann. Surg.99(1), 116–125 (1934).
   PubMedGoogle Scholar
• Crockford PM, Bain GO. Fine-needle aspiration biospy of the thyroid. Can. Med. Assoc. J.110(9), 1029–1032 (1974).
   PubMedGoogle Scholar
• Einhorn J, Franzen S. Thin-needle biopsy in the diagnosis of tumours of the thyroid. Acta Radiol.58, 321 (1962).
   Web of Science ®Google Scholar
• Fujimoto Y, Oka A, Omoto R, Hirose M. Ultrasound scanning of the thyroid gland as a new diagnostic approach. Ultrasonics5, 177–180 (1967).
   PubMed Web of Science ®Google Scholar
• Rudowski W. Critical evaluation of aspiration biopsy in the diagnosis of tumours. Am. J. Surg.95, 40–44 (1958).
   PubMedGoogle Scholar
• Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J. Am. Med. Assoc.132(14), 838–847 (1946).
   PubMed Web of Science ®Google Scholar
• Smithers DW. The treatment of cancer of the thyroid with radioactive iodine. J. R. Soc. Med.45(6), 339–340 (1952).
   Google Scholar
• Soderstrom N. Puncture of goiters for aspiration biopsy. Acta. Med. Scand.144, 237–244 (1952).
   PubMedGoogle Scholar
• Frates MC, Benson CB, Charboneau JW et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q.22(4), 231–238; discussion 239–240 (2006).
   PubMedGoogle Scholar
• Baloch ZW, LiVolsi VA, Asa SL et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn. Cytopathol.36(6), 425–437 (2008).
   PubMed Web of Science ®Google Scholar
• British Thyroid Association, Royal College of Physicians. Guidelines for the Management of Thyroid Cancer (2nd Edition). Report of the Thyroid Cancer Guidelines Update Group. Perros P (Ed.). Royal College of Physicians, London, UK (2007).
   Google Scholar
• Cooper DS, Doherty GM, Haugen BR et al. Revised american thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid19(11), 1167–1214 (2009).
   PubMed Web of Science ®Google Scholar
• Gharib H, Papini E, Paschke R et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr. Pract.16(3), 468–475 (2010).
   PubMedGoogle Scholar
• Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v214–v219 (2010).
   PubMed Web of Science ®Google Scholar
• Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab.91(1), 313–319 (2006).
   PubMed Web of Science ®Google Scholar
• Grieco M, Santoro M, Berlingieri MT et al. Molecular cloning of PTC, a new oncogene found activated in human thyroid papillary carcinomas and their lymph node metastases. Ann. NY Acad. Sci.551, 380–381 (1988).
   PubMedGoogle Scholar
• Lemoine NR, Mayall ES, Wyllie FS et al. Activated ras oncogenes in human thyroid cancers. Cancer Res.48(16), 4459–4463 (1988).
   PubMed Web of Science ®Google Scholar
• Suarez HG, Du Villard JA, Caillou B et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene2(4), 403–406 (1988).
   PubMedGoogle Scholar
• Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science289(5483), 1357–1360 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen Y, Xing M, Mambo E et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst.95(8), 625–627 (2003).
   PubMed Web of Science ®Google Scholar
• Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res.63(7), 1454–1457 (2003).
   PubMed Web of Science ®Google Scholar
• Saji M, Ringel MD. The PI3K–Akt–mTOR pathway in initiation and progression of thyroid tumors. Mol. Cell. Endocrinol.321(1), 20–28 (2010).
   PubMed Web of Science ®Google Scholar
• Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid20(7), 697–706 (2010).
   PubMed Web of Science ®Google Scholar
• Menon MP, Khan A. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J. Clin. Pathol.62(11), 978–985 (2009).
   PubMedGoogle Scholar
• Pallante P, Visone R, Croce CM, Fusco A. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr. Relat. Cancer17(1), F91–F104 (2010).
   Google Scholar
• Kondo T, Asa SL, Ezzat S. Epigenetic dysregulation in thyroid neoplasia. Endocrinol. Metab. Clin. North. Am.37(2), 389–400, ix (2008).
   PubMedGoogle Scholar
• Eszlinger M, Krohn K, Kukulska A, Jarzab B, Paschke R. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr. Rev.28(3), 322–338 (2007).
   PubMedGoogle Scholar
• Laubenbacher R, Hower V, Jarrah A et al. A systems biology view of cancer. Biochim. Biophys. Acta.1796(2), 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Chan JKC, Hirokawa M, Evans H et al. Tumours of the thyroid and parathyroid. In: WHO Classification of Tumours; Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU, Eng C (Eds). IARC Press, Lyon, France, 49–175 (2004).
   Google Scholar
• Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. Diagn. Cytopathol.26(1), 41–44 (2002).
   PubMed Web of Science ®Google Scholar
• Raber W, Kaserer K, Niederle B, Vierhapper H. Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. Thyroid10(8), 709–712 (2000).
   PubMed Web of Science ®Google Scholar
• Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer111(5), 306–315 (2007).
   PubMed Web of Science ®Google Scholar
• Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Am. J. Clin. Pathol.132(5), 658–665 (2009).
   PubMed Web of Science ®Google Scholar
• Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S. Implications of the proposed thyroid fine-needle aspiration category of “follicular lesion of undetermined significance”: a five-year multi-institutional analysis. Diagn. Cytopathol.37(10), 710–714 (2009).
   PubMed Web of Science ®Google Scholar
• Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer Cytopathol.117(3), 195–202 (2009).
   PubMedGoogle Scholar
• Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol.118(1), 17–23 (2010).
   PubMed Web of Science ®Google Scholar
• Vasko VV, Gaudart J, Allasia C et al. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur. J. Endocrinol.151(6), 779–786 (2004).
   PubMedGoogle Scholar
• Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland: Follicular Carcinomas. Papillary Carcinomas. In: Atlas of Tumor Pathology. Rosai J, Sobin LH (Eds). Armed Forces Institute of Pathology, DC, USA, 49–121 (1992).
   Google Scholar
• Franc B, de la Salmoniere P, Lange F et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum. Pathol.34(11), 1092–1100 (2003).
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Erickson LA, Casey MB et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am. J. Surg. Pathol.28(10), 1336–1340 (2004).
   PubMedGoogle Scholar
• Sobrinho-Simoes M, Eloy C, Vinagre J, Soares P. Molecular pathology of thyroid tumors: diagnostic and prognostic relevance. Int. J. Surg. Pathol.18(3 Suppl.), 209S–212S (2010).
   Google Scholar
• Liu J, Singh B, Tallini G et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer107(6), 1255–1264 (2006).
   PubMed Web of Science ®Google Scholar
• Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA. Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid19(2), 119–127 (2009).
   PubMedGoogle Scholar
• Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metab.22(6), 955–969 (2008).
   PubMed Web of Science ®Google Scholar
• Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology145(12), 5448–5451 (2004).
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev.28(7), 742–762 (2007).
   PubMed Web of Science ®Google Scholar
• Dwight T, Thoppe SR, Foukakis T et al. Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab.88(9), 4440–4445 (2003).
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Lynch RA, Biddinger PW et al.RAS point mutations and PAX8-PPAR γ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab.88(5), 2318–2326 (2003).
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid19(12), 1351–1361 (2009).
   PubMed Web of Science ®Google Scholar
• Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab.88(6), 2745–2752 (2003).
   PubMed Web of Science ®Google Scholar
• Kang DY, Kim KH, Kim JM et al. High prevalence of RET, RAS, and ERK expression in Hashimoto’s thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid17(11), 1031–1038 (2007).
   PubMedGoogle Scholar
• Rhoden KJ, Unger K, Salvatore G et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab.91(6), 2414–2423 (2006).
   PubMed Web of Science ®Google Scholar
• Marques AR, Espadinha C, Catarino AL et al. Expression of PAX8-PPAR γ 1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab.87(8), 3947–3952 (2002).
   PubMed Web of Science ®Google Scholar
• Arora N, Scognamiglio T, Zhu B, Fahey TJ 3rd. Do benign thyroid nodules have malignant potential? An evidence-based review. World. J. Surg.32(7), 1237–1246 (2008).
   PubMedGoogle Scholar
• Kim CS, Zhu X. Lessons from mouse models of thyroid cancer. Thyroid19(12), 1317–1331 (2009).
   PubMedGoogle Scholar
• Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol. Cell. Endocrinol.322(1–2), 8–28 (2010).
   PubMed Web of Science ®Google Scholar
• Xing M, Clark D, Guan H et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol.27(18), 2977–2982 (2009).
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer12(2), 245–262 (2005).
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell.5(4), 303–304 (2004).
   PubMedGoogle Scholar
• Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell116(6), 855–867 (2004).
   PubMed Web of Science ®Google Scholar
• Mitsutake N, Miyagishi M, Mitsutake S et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC–RAS–BRAF pathway in papillary thyroid carcinogenesis. Endocrinology147(2), 1014–1019 (2006).
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Z, Condouris S, Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab.92(6), 2264–2271 (2007).
   PubMed Web of Science ®Google Scholar
• Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr., Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res.65(6), 2465–2473 (2005).
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab.90(12), 6373–6379 (2005).
   PubMed Web of Science ®Google Scholar
• Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg.246(3), 466–470; discussion 470–461 (2007).
   PubMed Web of Science ®Google Scholar
• Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab.93(10), 3943–3949 (2008).
   PubMed Web of Science ®Google Scholar
• Riesco-Eizaguirre G, Rodriguez I, De la Vieja A et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res.69(21), 8317–8325 (2009).
   PubMedGoogle Scholar
• Barollo S, Pennelli G, Vianello F et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131) I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur. J. Endocrinol.163(4), 659–663 (2010).
   PubMed Web of Science ®Google Scholar
• Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell. Endocrinol.322(1–2), 29–37 (2010).
   PubMed Web of Science ®Google Scholar
• Marchetti I, Lessi F, Mazzanti CM et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid19(8), 837–842 (2009).
   PubMed Web of Science ®Google Scholar
• Yip L, Nikiforova MN, Carty SE et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery146(6), 1215–1223 (2009).
   PubMed Web of Science ®Google Scholar
• Adeniran AJ, Zhu Z, Gandhi M et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol.30(2), 216–222 (2006).
   PubMed Web of Science ®Google Scholar
• Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab.85(3), 1170–1175 (2000).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of RET oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res.57(9), 1690–1694 (1997).
   PubMed Web of Science ®Google Scholar
• Rabes HM, Demidchik EP, Sidorow JD et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res.6(3), 1093–1103 (2000).
   PubMed Web of Science ®Google Scholar
• Unger K, Zitzelsberger H, Salvatore G et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab.89(9), 4272–4279 (2004).
   PubMedGoogle Scholar
• Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab.91(9), 3603–3610 (2006).
   PubMed Web of Science ®Google Scholar
• Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J. Surg. Res.150(1), 49–52 (2008).
   PubMed Web of Science ®Google Scholar
• Jhiang SM, Sagartz JE, Tong Q et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology137(1), 375–378 (1996).
   PubMed Web of Science ®Google Scholar
• Santoro M, Chiappetta G, Cerrato A et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene12(8), 1821–1826 (1996).
   PubMed Web of Science ®Google Scholar
• Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol.50(4), 529–535 (1999).
   PubMed Web of Science ®Google Scholar
• Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer6(4), 292–306 (2006).
   PubMed Web of Science ®Google Scholar
• Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer116(12), 2974–2983 (2010).
   PubMed Web of Science ®Google Scholar
• Di Cristofaro J, Marcy M, Vasko V et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum. Pathol.37(7), 824–830 (2006).
   PubMedGoogle Scholar
• Freitas BC, Cerutti JM. Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol. Cell. Endocrinol.321(1), 77–85 (2010).
   PubMedGoogle Scholar
• Volante M, Rapa I, Gandhi M et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J. Clin. Endocrinol. Metab.94(12), 4735–4741 (2009).
   PubMed Web of Science ®Google Scholar
• Eberhardt NL, Grebe SK, McIver B, Reddi HV. The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol. Cell. Endocrinol.321(1), 50–56 (2010).
   PubMedGoogle Scholar
• Marques AR, Espadinha C, Frias MJ et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours. Br. J. Cancer91(4), 732–738 (2004).
   PubMedGoogle Scholar
• Sahin M, Allard BL, Yates M et al. PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J. Clin. Endocrinol. Metab.90(1), 463–468 (2005).
   PubMed Web of Science ®Google Scholar
• Reddi HV, Madde P, Marlow LA et al. Expression of the PAX8/PPARγ fusion protein is associated with decreased neovascularization in vivo: impact on tumorigenesis and disease prognosis. Genes Cancer1(5), 480–492 (2010).
   PubMedGoogle Scholar
• Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J. Clin. Endocrinol. Metab.95(3), 1365–1369 (2010).
   PubMed Web of Science ®Google Scholar
• Musholt TJ, Fottner C, Weber MM et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J. Surg.34(11), 2595–2603 (2010).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab.94(6), 2092–2098 (2009).
   PubMed Web of Science ®Google Scholar
• Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg.242(3), 353–361; discussion 361–353 (2005).
   PubMedGoogle Scholar
• Lubitz CC, Ugras SK, Kazam JJ et al. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J. Mol. Diagn.8(4), 490–498; quiz 528 (2006).
   PubMedGoogle Scholar
• Moses W, Weng J, Sansano I et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J. Surg.34(11), 2589–2594 (2010).
   PubMed Web of Science ®Google Scholar
• Ambros V. microRNAs: tiny regulators with great potential. Cell107(7), 823–826 (2001).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA102(52), 19075–19080 (2005).
   PubMed Web of Science ®Google Scholar
• Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab.91(9), 3584–3591 (2006).
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab.93(5), 1600–1608 (2008).
   PubMed Web of Science ®Google Scholar
• Chen YT, Kitabayashi N, Zhou XK, Fahey TJ 3rd, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol.21(9), 1139–1146 (2008).
   PubMedGoogle Scholar
• Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer13(2), 497–508 (2006).
   PubMed Web of Science ®Google Scholar
• Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M, Schmid KW. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br. J. Cancer102(2), 376–382 (2010).
   PubMed Web of Science ®Google Scholar
• Tetzlaff MT, Liu A, Xu X et al. Differential expression of miRNAs in papillary thyroid carcinoma compared with multinodular goiter using formalin fixed paraffin embedded tissues. Endocr. Pathol.18(3), 163–173 (2007).
   PubMed Web of Science ®Google Scholar
• Chou CK, Chen RF, Chou FF et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid20(5), 489–494 (2010).
   PubMed Web of Science ®Google Scholar
• Mazeh H, Mizrahi I, Halle D et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid21(2), 111–118 (2011).
   PubMed Web of Science ®Google Scholar
• Yip L, Kelly L, Shuai Y et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol.18(7), 2035–2041 (2011).
   PubMed Web of Science ®Google Scholar
• Brioschi M, Fischer J, Cairoli R et al. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia12(11), 866–876 (2011).
   Google Scholar
• Conti A, Aguennouz M, La Torre D et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors. J. Neurooncol.93(3), 325–332 (2009).
   PubMed Web of Science ®Google Scholar
• Di Leva G, Gasparini P, Piovan C et al. MicroRNA cluster 221–222 and estrogen receptor α interactions in breast cancer. J. Natl Cancer Inst.102(10), 706–721 (2011).
   Google Scholar
• Garofalo M, Di Leva G, Romano G et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell16(6), 498–509 (2009).
   PubMed Web of Science ®Google Scholar
• Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res.69(4), 1279–1283 (2009).
   PubMed Web of Science ®Google Scholar
• Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem.283(44), 29897–29903 (2008).
   PubMed Web of Science ®Google Scholar
• Patnaik SK, Kannisto E, Mallick R, Yendamuri S. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PloS One6(7), e22379 (2011).
   Google Scholar
• Stinson S, Lackner MR, Adai AT et al. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci. Signal.4(186), pt5 (2011).
   PubMed Web of Science ®Google Scholar
• Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res.69(8), 3356–3363 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J, Han L, Ge Y et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int. J. Oncol.36(4), 913–920 (2011).
   Google Scholar
• Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology148(3), 948–953 (2007).
   PubMed Web of Science ®Google Scholar
• Smith JA, Fan CY, Zou C, Bodenner D, Kokoska MS. Methylation status of genes in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg.133(10), 1006–1011 (2007).
   PubMed Web of Science ®Google Scholar
• Ringel MD, Anderson J, Souza SL et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod. Pathol.14(4), 289–296 (2001).
   PubMedGoogle Scholar
• Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res.13(4), 1341–1349 (2007).
   PubMed Web of Science ®Google Scholar
• Zuo H, Gandhi M, Edreira MM et al. Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res.70(4), 1389–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Schagdarsurengin U, Richter AM, Wohler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics4(8), 571–576 (2009).
   PubMed Web of Science ®Google Scholar
• Guan H, Ji M, Hou P et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer113(2), 247–255 (2008).
   PubMedGoogle Scholar
• Kondo T, Nakazawa T, Ma D et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab. Invest.89(7), 791–799 (2009).
   PubMedGoogle Scholar
• Hu S, Liu D, Tufano RP et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer119(10), 2322–2329 (2006).
   PubMed Web of Science ®Google Scholar
• Fujarewicz K, Jarzab M, Eszlinger M et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr. Relat. Cancer14(3), 809–826 (2007).
   PubMed Web of Science ®Google Scholar
• Fontaine JF, Mirebeau-Prunier D, Raharijaona M et al. Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers. PloS One4(10), e7632 (2009).
   Google Scholar
• Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J. Clin. Oncol.24(31), 5043–5051 (2006).
   PubMed Web of Science ®Google Scholar
• Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin. Cancer Res.14(15), 4735–4742 (2008).
   PubMedGoogle Scholar
• Takano T, Yamada H. Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma. Endocr. J.56(1), 9–16 (2009).
   PubMedGoogle Scholar
• Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E. Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer113(5), 930–935 (2008).
   PubMedGoogle Scholar
• Weber F, Shen L, Aldred MA et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J. Clin. Endocrinol. Metab.90(5), 2512–2521 (2005).
   PubMed Web of Science ®Google Scholar
• Arora N, Scognamiglio T, Lubitz CC et al. Identification of borderline thyroid tumors by gene expression array analysis. Cancer115(23), 5421–5431 (2009).
   PubMedGoogle Scholar
• Denning KM, Smyth PC, Cahill SF et al. A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Mod. Pathol.20(10), 1095–1102 (2007).
   PubMedGoogle Scholar
• Prasad NB, Somervell H, Tufano RP et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin. Cancer Res.14(11), 3327–3337 (2008).
   PubMed Web of Science ®Google Scholar
• Chudova D, Wilde JI, Wang ET et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J. Clin. Endocrinol. Metab.95(12), 5296–5304 (2010).
   PubMed Web of Science ®Google Scholar
• Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch. Pathol. Lab. Med.132(3), 359–372 (2008).
   PubMed Web of Science ®Google Scholar
• de Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br. J. Cancer98(4), 818–823 (2008).
   PubMed Web of Science ®Google Scholar
• Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid10(4), 349–357 (2000).
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, D’Alessandria C, Parisella MG et al. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PloS One3(11), e3768 (2008).
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Gasbarri A, Papotti M et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet357(9269), 1644–1650 (2001).
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Orlandi F, Saggiorato E et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol.9(6), 543–549 (2008).
   PubMed Web of Science ®Google Scholar
• Carpi A, Naccarato AG, Iervasi G et al. Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br. J. Cancer95(2), 204–209 (2006).
   PubMed Web of Science ®Google Scholar
• Carpi A, Rossi G, Coscio GD et al. Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: a prospective cohort study. Ann. Med.42(1), 70–78 (2010).
   PubMed Web of Science ®Google Scholar
• Chiu CG, Strugnell SS, Griffith OL et al. Diagnostic utility of galectin-3 in thyroid cancer. Am. J. Pathol.176(5), 2067–2081 (2010).
   PubMed Web of Science ®Google Scholar
• Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res.57(23), 5272–5276 (1997).
   PubMed Web of Science ®Google Scholar
• Cecchinelli B, Lavra L, Rinaldo C et al. Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol. Cell. Biol.26(12), 4746–4757 (2006).
   PubMedGoogle Scholar
• Lavra L, Rinaldo C, Ulivieri A et al. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PloS One6(6), e20665 (2011).
   PubMed Web of Science ®Google Scholar
• Lin CI, Whang EE, Abramson MA et al. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem. Biophys. Res. Commun.379(2), 626–631 (2009).
   PubMedGoogle Scholar
• Lin CI, Whang EE, Donner DB et al. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol. Cancer Res.7(10), 1655–1662 (2009).
   PubMed Web of Science ®Google Scholar
• Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat. Rev. Cancer5(1), 29–41 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshii T, Inohara H, Takenaka Y et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int. J. Oncol.18(4), 787–792 (2001).
   PubMedGoogle Scholar
• Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn. Cytopathol.31(6), 392–396 (2004).
   PubMed Web of Science ®Google Scholar
• Mehrotra P, Okpokam A, Bouhaidar R et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology45(5), 493–500 (2004).
   PubMedGoogle Scholar
• Bartolazzi A, Bellotti C, Sciacchitano S. Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Appl. Immunohistochem. Mol. Morphol. (2011) (Epub ahead of print).
   Google Scholar
• Bartolazzi A, Bussolati G. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology48(2), 212–213 (2006).
   PubMedGoogle Scholar
• Bartolazzi A, Papotti M, Orlandi F. Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. J. Clin. Endocrinol. Metab.88(2), 950; author reply 950–951 (2003).
   PubMed Web of Science ®Google Scholar
• Cerutti JM, Delcelo R, Amadei MJ et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin. Invest.113(8), 1234–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Cerutti JM, Latini FR, Nakabashi C et al. Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin. Cancer Res.12(11 Pt 1), 3311–3318 (2006).
   PubMed Web of Science ®Google Scholar
• Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur. J. Endocrinol.158(3), 375–384 (2008).
   PubMedGoogle Scholar
• Sapio MR, Guerra A, Posca D et al. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr. Relat. Cancer14(4), 1089–1097 (2007).
   PubMed Web of Science ®Google Scholar
• Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature379(6564), 458–460 (1996).
   PubMed Web of Science ®Google Scholar
• Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid10(4), 321–330 (2000).
   PubMedGoogle Scholar
• Robbins J, Merino MJ, Boice JD Jr et al. Thyroid cancer: a lethal endocrine neoplasm. Ann. Intern. Med.115(2), 133–147 (1991).
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Ringel MD. Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J. Clin. Endocrinol. Metab.88(5), 1947–1960 (2003).
   PubMedGoogle Scholar
• Vadysirisack DD, Venkateswaran A, Zhang Z, Jhiang SM. MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner. Endocr. Relat. Cancer14(2), 421–432 (2007).
   PubMedGoogle Scholar
• Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer13(3), 797–826 (2006).
   PubMed Web of Science ®Google Scholar
• Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid20(9), 965–974 (2010).
   PubMed Web of Science ®Google Scholar
• Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J. Clin. Endocrinol. Metab.95(2), 820–828 (2010).
   PubMed Web of Science ®Google Scholar
• Sherman SI. Targeted therapy of thyroid cancer. Biochem. Pharmacol.80(5), 592–601 (2010).
   PubMed Web of Science ®Google Scholar
• Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M. Molecular targeted therapies for patients with refractory thyroid cancer. Clin. Oncol. (R. Coll. Radiol.)22(6), 448–455 (2010).
   PubMedGoogle Scholar
• Duntas LH, Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid20(12), 1351–1358 (2010).
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol.61(4), 535–548 (2008).
   PubMed Web of Science ®Google Scholar
• Hong DS, Sebti SM, Newman RA et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin. Cancer Res.15(22), 7061–7068 (2009).
   PubMed Web of Science ®Google Scholar
• Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J. Am. Acad. Dermatol.61(3), 522–527 (2009).
   PubMedGoogle Scholar
• Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol. Surg.35(11), 1766–1770 (2009).
   PubMed Web of Science ®Google Scholar
• Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr. Relat. Cancer17(3), R233–R244 (2010).
   PubMed Web of Science ®Google Scholar
• Hoperia V, Larin A, Jensen K, Bauer A, Vasko V. Thyroid fine needle aspiration biopsies in children: study of cytological-histological correlation and immunostaining with thyroid peroxidase monoclonal antibodies. Int. J. Pediatr. Endocrinol.2010, 690108 (2010).
   PubMedGoogle Scholar
• Bevers TB, Anderson BO, Bonaccio E et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J. Natl Compr. Canc. Netw.7(10), 1060–1096 (2009).
   PubMed Web of Science ®Google Scholar